PET-2-guided escalated BEACOPP for advanced nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the randomized German Hodgkin Study Group HD18 study.

导出原文传递

翻译打印收藏纠错

作者： D A,Eichenauer ^[1] ; S,Kreissl ^[2] ; I,Bühnen ^[2] ; C,Baues ^[3] ; C,Kobe ^[4] ; L,van Heek ^[4] ; H,Goergen ^[2] ; M,Fuchs ^[2] ; S,Hartmann ^[5] ; B,von Tresckow ^[6] ; A,Engert ^[2] ; P,Borchmann ^[2]

作者单位： First Department of Internal Medicine, Center for Integrated Oncology Aachen, Bonn, Cologne and Dusseldorf, University of Cologne, Cologne, Germany; German Hodgkin Study Group (GHSG), University Hospital Cologne, Cologne, Germany. Electronic address: dennis.eichenauer@uk-koeln.de. ^[1] First Department of Internal Medicine, Center for Integrated Oncology Aachen, Bonn, Cologne and Dusseldorf, University of Cologne, Cologne, Germany; German Hodgkin Study Group (GHSG), University Hospital Cologne, Cologne, Germany. ^[2] German Hodgkin Study Group (GHSG), University Hospital Cologne, Cologne, Germany; Department of Radiation Oncology, University of Cologne, Cologne, Germany. ^[3] German Hodgkin Study Group (GHSG), University Hospital Cologne, Cologne, Germany; Department of Nuclear Medicine, University of Cologne, Cologne, Germany. ^[4] Senckenberg Institute of Pathology, Goethe University Frankfurt, Frankfurt am Main, Germany. ^[5] First Department of Internal Medicine, Center for Integrated Oncology Aachen, Bonn, Cologne and Dusseldorf, University of Cologne, Cologne, Germany; German Hodgkin Study Group (GHSG), University Hospital Cologne, Cologne, Germany; Clinic for Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany. ^[6]